Cabaletta’s Early Data Shows Potential for Treating Autoimmune Diseases
The company reported positive results in the first two patients who received its new CAR T therapy, CABA-201, which aims to treat the autoimmune diseases lupus and myositis.
Heirloom Builds Direct Carbon Capture Facility
Heirloom has announced the first phase of a decarbonization project to create two Direct Air Capture (DAC) facilities in North Western Louisiana,
Development of RNA Therapeutics Targets Neurological Diseases
The collaboration combines Ascidian's RNA exon editing technology with Roche's expertise in CNS delivery to create novel treatments for hard-to-treat neurological conditions.
PCI and PACT Host AI Event for Philly Tech Week
PCI and the Philadelphia Alliance for Capital and Technologies (PACT) jointly presented a recent event called “AI Nexus: Shaping Tomorrow’s Intelligence."
A Rare Patient Mutation May Help Lead to More Effective Treatments for Genetic Bone Disease
Davis' relatively benign symptomology is attributed to low levels of the inflammatory protein MMP-9, which seems to prevent the characteristic abnormal bone formation.
Penn Engineering’s Deep Jariwala and Troy Olsson Develop Heat-resistant Memory Device that can Withstand Extreme Temperatures
This device, whose heat tolerance far surpasses existing commercial storage technologies, could help to facilitate computing under extreme conditions like deep-earth drilling and space missions.
Penn Researchers Create Novel mRNA-based Avian Flu Vaccine
Penn Medicine researchers have developed an mRNA vaccine for the H5N1 avian flu using techniques similar to those enabling mRNA-based COVID-19 vaccines.
EU Approves Expanded Use of Sobi’s Aspaveli® for Rare Blood Disorder
The European Commission has approved Sobi's drug Aspaveli® (pegcetacoplan) for broader use in adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder.
Exyn Technologies Partners with Measur to Expand Canadian Footprint
Measur plans to bring Exyn's cutting-edge technologies like the Nexys 3D SLAM LiDAR payload system to market.
Carisma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT-0525, Appoints Eugene P. Kennedy as Chief Medical Officer
Carisma announced the dosing of its first patient in its Phase 1 trial for CT-0525, an innovative CAR-Monocyte therapy targeting HER2-overexpressing solid tumors.